States cut Medicaid for GLP‑1s
Several U.S. states have begun dropping Medicaid coverage for GLP‑1 weight‑loss drugs as demand and costs rise, a move reported by The Guardian amid broader access and affordability debates. (theguardian.com) Reuters framed the sector as facing an economic stress test, noting monthly treatment costs near $1,000 and uncertainty about long‑term demand if prices or consumer spending shift. (reuters.com)
States are starting to drop Medicaid coverage for glucagon-like peptide-1 weight-loss drugs as prescription costs climb. (theguardian.com, kff.org) California’s Medicaid program, Medi-Cal, stopped covering Wegovy, Zepbound, and Saxenda for weight loss on January 1, 2026. State notices said prior approvals expired on December 31, 2025, and claims after January 1 would be denied for weight-loss use. (medi-calrx.dhcs.ca.gov, medi-calrx.dhcs.ca.gov) Massachusetts is moving in the same direction. MassHealth said in March 2026 that it expects to stop covering anti-obesity drugs, including glucagon-like peptide-1 medicines used for weight loss, effective July 1, 2026. (mass.gov, mass.gov) These drugs are expensive enough to reshape state budgets. Reuters said monthly treatment costs run near $1,000, while Novo Nordisk’s consumer materials show Wegovy cash-pay programs in 2026 at hundreds of dollars a month even after discounts. (reuters.com, novocare.com) Medicaid does not treat these prescriptions like insulin or antibiotics. KFF said states generally must cover most Food and Drug Administration approved drugs, but a long-standing exception lets them decide whether to cover drugs used for weight loss. (kff.org) That exception has produced a patchwork. KFF found 13 state Medicaid fee-for-service programs covered glucagon-like peptide-1 drugs for obesity treatment as of January 2026, down from 16 state programs reporting such coverage as of October 1, 2025, in KFF’s budget survey. (kff.org, kff.org) Coverage rules also depend on why the drug is prescribed. KFF said Medicaid coverage is required when these medicines are used for type 2 diabetes, cardiovascular disease, or sleep apnea, but obesity treatment remains optional for states. (kff.org) Federal officials are trying to keep some states in the market. The Centers for Medicare & Medicaid Services announced the BALANCE model on December 23, 2025, and said state Medicaid agencies can begin joining in May 2026 so the agency can negotiate pricing and coverage terms for weight-management glucagon-like peptide-1 drugs. (cms.gov, cms.gov) For patients, the result is simpler than the policy language: the same drug can stay covered for diabetes and lose coverage for weight loss, depending on the state and the diagnosis code on the prescription. (medi-calrx.dhcs.ca.gov, kff.org)
